Emergent BioSolutions Inc. (EBS) P/E Ratio History
Historical price-to-earnings valuation from 2007 to 2025
Loading P/E history...
EBS Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Emergent BioSolutions Inc. (EBS) trades at a price-to-earnings ratio of 9.8x, with a stock price of $9.13 and trailing twelve-month earnings per share of $1.00.
The current P/E is 83% below its 5-year average of 59.1x. Over the past five years, EBS's P/E has ranged from a low of 2.6x to a high of 714.2x, placing the current valuation at the 10th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, EBS trades at a 56% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, EBS trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our EBS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
EBS P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $339M | 14.3Lowest | - | -60% | |
| $930M | 147.8 | - | +107%Best | |
| $151B | 19.5 | - | -4% | |
| $277B | 15.4 | 0.73Best | +8% | |
| $536B | 38.4 | - | -58% | |
| $92B | 29.2 | 0.75 | +15% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
EBS Historical P/E Data (2007–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $12.36 | $0.84 | 14.7x | -59% |
| FY2025 Q3 | $8.82 | $1.29 | 6.8x | -81% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $6.38 | $2.44 | 2.6x | -93% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $20.99 | $0.78 | 27.0x | -24% |
| FY2022 Q2 | $31.04 | $1.69 | 18.4x | -48% | |
| FY2022 Q1 | $41.06 | $2.91 | 14.1x | -60% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $43.47 | $4.26 | 10.2x | -71% |
| FY2021 Q3 | $50.07 | $4.20 | 11.9x | -67% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $62.99 | $5.54 | 11.4x | -68% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $92.91 | $7.18 | 12.9x | -64% |
| FY2020 Q4 | $89.60 | $5.66 | 15.8x | -56% | |
| FY2020 Q3 | Wed Sep 30 2020 00:00:00 GM | $103.33 | $3.11 | 33.2x | -7% |
Average P/E for displayed period: 35.7x
See EBS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EBS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EBS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEBS — Frequently Asked Questions
Quick answers to the most common questions about buying EBS stock.
Is EBS stock overvalued or undervalued?
EBS trades at 9.8x P/E, below its 5-year average of 59.1x. At the 10th percentile of historical range, the stock is priced at a discount to its own history.
How does EBS's valuation compare to peers?
Emergent BioSolutions Inc. P/E of 9.8x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is EBS's PEG ratio?
EBS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2007-2025.